Aethlon Medical Stock Price, News & Analysis

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology firm, will be presenting at the HC Wainwright 22nd Annual Global Investment Conference on Monday, Sept. 14, 2020, at 2:00 p.m. EDT. The presentation will be led by CEO Timothy C. Rodell and will be available for replay for 90 days post-presentation. Aethlon’s primary focus is the Hemopurifier^®, a breakthrough immunotherapeutic device targeting cancer and life-threatening viral infections. The Hemopurifier aims to reduce tumor-derived exosomes that contribute to immune suppression and metastasis.

Aethlon Medical, Inc. (Nasdaq: AEMD) will present at the LD Micro 500 virtual investor conference on September 3, 2020, at 11:40 AM PT. CEO Timothy C. Rodell, MD, will also hold one-on-one meetings with investors throughout the day. The presentation will be accessible live and later as a replay on Aethlon's website. The LD Micro 500 runs from September 1-4, featuring 500 micro-cap companies. Aethlon's Hemopurifier® is a breakthrough device targeting cancer and viral infections, focusing on depleting tumor-derived exosomes.

Aethlon Medical, Inc. (AEMD) announced its financial results for Q1 2020, reporting a net loss of approximately $1.4 million, reduced from $2.1 million in Q1 2019. Operating expenses decreased by 12% to $1.4 million, attributed to lower payroll and professional fees. Aethlon continues developing its Hemopurifier®, now entering clinical trials for advanced cancer and SARS-CoV-2 treatment. The company received a $3.5 million NIH grant to support exosome research. As of June 30, 2020, it reported a cash balance of $15.7 million.

Aethlon Medical, Inc. (AEMD) announced a $3.5 million grant from the NIH's NIDCR for a collaborative study on head and neck cancer with the UPMC Hillman Cancer Center. This project will investigate the role of tumor-derived exosomes and assess the impact of Aethlon's Hemopurifier device in enhancing immune therapy responses. Led by Drs. Theresa Whiteside and Annette Marleau, the five-year study aims to improve treatment outcomes for patients suffering from recurrent and metastatic head and neck cancer.

Aethlon Medical, Inc. (AEMD) announced it will release its financial results for Q1 FY2021 on August 11, 2020, at 4:15 PM Eastern Time. This is for the quarter ending June 30, 2020. A conference call will follow at 4:30 PM Eastern Time, where management will discuss the results and recent developments. The call will include a Q&A session. The Aethlon Hemopurifier, a Breakthrough Device for cancer and viral infections, continues to progress in addressing critical health needs.

Aethlon Medical, Inc. (AEMD) reported its financial results for the fiscal year ending March 31, 2020. The company generated government contract revenue of $650,187, up from $229,625 in the prior year. Operating expenses rose by 6% to approximately $6.58 million. The net loss increased to around $6.38 million, compared to $6.22 million in the previous year. Aethlon continues developing its Hemopurifier device, aiming to initiate clinical trials for advanced cancers and recently received FDA approval to treat COVID-19 patients. As of March 31, 2020, the company had a cash balance of about $9.6 million.

Aethlon Medical, Inc. (AEMD) presented encouraging data on its Hemopurifier at the AACR Virtual Annual Meeting II on June 22, 2020. The data demonstrated that the Hemopurifier effectively captures and removes tumor-derived exosomes from fluid samples of cancer patients, including those with head and neck, melanoma, ovarian, esophageal, and breast cancers. CEO Timothy C. Rodell emphasized that targeting these exosomes could enhance cancer treatment outcomes. The Hemopurifier is recognized as an FDA-designated "Breakthrough Device" for advanced cancer and critical viral infections.

Aethlon Medical (Nasdaq: AEMD) announced FDA approval for a supplement to its Investigational Device Exemption (IDE) enabling the Hemopurifier® to be tested in COVID-19 patients. The feasibility study will include up to 40 subjects in ICUs with acute lung injury and severe symptoms. The Hemopurifier, previously tested for hepatitis C and Ebola, is designated as a Breakthrough Device for life-threatening viral infections and advanced cancer. CEO Timothy C. Rodell believes the device could improve outcomes for severely affected COVID-19 patients.

Aethlon Medical, Inc. (Nasdaq: AEMD) announced it will release its financial results for Q4 FY2020 on June 25, 2020, at 4:15 PM Eastern Time. A conference call is scheduled for the same day at 4:30 PM Eastern, where management will review results and corporate developments, followed by a Q&A session. The Hemopurifier®, Aethlon's immunotherapeutic device, has received FDA's Breakthrough Device designations for cancer and viral infections, aiming to address critical unmet needs in global health.